Tag Archives: T-cell

November, 2017

29 November
bluebird bio Acquires North Carolina Manufacturing Facility and Executes Multiple Global Supply Agreements

CAMBRIDGE, Mass.–(BUSINESS WIRE)–bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene and cell therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced it has acquired a 125,000-square foot manufacturing facility in Durham, North Carolina. Once construction and validation is complete, the site …
Share

4 October
Amgen and CytomX Enter Immuno-Oncology Collaboration

THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Oct. 3, 2017 /PRNewswire/ — Amgen (NASDAQ: AMGN) and CytomX Therapeutics, Inc., (NASDAQ: CTMX) today announced that the companies have entered into a strategic collaboration in immuno-oncology. The companies will co-develop a CytomX Probody™ T-cell engaging bispecific against the Epidermal Growth Factor …
Share

4 January
Jounce Therapeutics Files for $75M IPO

CAMBRIDGE, Mass., January 3, 2017 –Jounce Therapeutics, a clinical-stage immuno-oncology company, has filed an initial public offering through which it hopes to raise $75 million in 2017. The Cambridge, MA-based company was founded in 2012 and employs a two-pronged approach to therapy development: using a translational science platform that targets …
Share
4 January
Lycera’s RORgamma Agonist to Begin Phase 1 Trials

NEW YORK and ANN ARBOR, Mich., January 4, 2017 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today the initiation of a Phase 1/2a clinical trial of the Company’s novel immuno-oncology therapeutic candidate LYC-55716, in patients with advanced, relapsed, or refractory solid tumors. “We …
Share

9 June
Celgene Enters $105 Million Cancer Immunotherapy Collaboration with Lycera

Celgene has entered into a new cancer immunotherapy deal that could provide privately-held Lycera Corp. up to $105 million-plus. Lycera announced the formation of an exclusive global collaboration with Celgene to advance Lycera’s proprietary pipeline for cancer and immune-mediated diseases. Lycera said that Celgene will license its portfolio of RORgamma …
Share